The Risk Factors Affecting Survival in Colorectal Cancer in Taiwan

Chao-Hsien LEE\(^1\), Shu-Chen CHENG\(^2\), Hong-Yi TUNG\(^{1,3}\), Shih-Chang CHANG\(^4\), Ching-Yun CHING\(^5\), *Shu-Fen WU\(^{1,5,6}\)

1. Dept. of Health Business Administration, Meiho University, Pingtung, Taiwan
2. Dept. of Cancer Registry Division, Cathay General Hospital, Taipei, Taiwan
3. Dept. of General Surgery, Yuan’s General Hospital, Kaohsiung, Kaohsiung, Taiwan
4. Dept. of Colorectal Surgery, Division of Surgery, Cathay General Hospital, Taipei, Taiwan
5. Dept. of Nursing, Yuan’s General Hospital, Kaohsiung, Taiwan
6. Dept. of Nursing, College of Medicine, I-Shou University, Kaohsiung, Taiwan

*Corresponding Author: Email: y355400@gmail.com

(Received 04 Sep 2016; accepted 15 May 2017)

Abstract

**Background:** Colorectal cancer is one of the most common malignancies in developed countries. The incidence of colorectal cancer (CRC) in Taiwan is rising. We aimed to determine the five-yr survival rate of patients diagnosed with CRC and determine factors affecting survival.

**Methods:** All patients were identified from the Taiwan Cancer Data Base of the Medical Center Hospital in North Taiwan from 2007 to 2013. Data were collected using medical records and the cancer database. In all, 869 patients with CRC were included. Survival analysis was performed using Kaplan-Meier curves, and differences between the curves were analyzed using the log-rank test. Cox proportional hazards regression models were used to analyze survival by each variable.

**Results:** The five-yr survival rate and the mean survival time after cancer diagnosis were 68.7% and 71.27±1.27 months. Perineural nerve invasion, distant metastasis, age, pathological differentiation grade, obstruction and regional lymph node metastasis were found to be independent predictors of the survival and prognosis of patients with CRC.

**Conclusion:** Perineural nerve invasion was an important factor related to the survival of CRC patients. Thus, the earlier detection of CRC might help improve survival.

**Keywords:** Risk factors, Survival, Colorectal cancer

Introduction

Colorectal cancer (CRC) is the second and third most commonly diagnosed cancer type in females and males, respectively, representing almost 10% of the global cancer incidence. These estimates correspond to age-standardized global incidence and mortality rates of 17.2 and 8.3 per 100000, respectively (1-3). There have been slightly more incident cases and deaths among men than among women in most parts of the world, except in the Caribbean (4). The reported incidence of CRC is highest in developed countries, including the United States, Canada, Australia, northwestern Europe, Japan, South Korea, and Singapore. However, the incidence and mortality
rates for CRC are higher in Japan, South Korea, Singapore, China, Hong Kong, Taiwan, and Thailand (5-7). In Taiwan, more than 15410 new cases of CRC were diagnosed in 2013. The incidence rate of CRC is 44.32 per 100000, and the mortality rate is 14.7 per 100000 in both sexes per year (8).

CRC imposes a considerable social economic burden, which includes direct medical care (e.g., treatment by stage at diagnosis, type of cost and disease phase), nonmedical costs, and productivity loss. Cancer survival is an indicator of the overall effectiveness of health services in the management of patients. The five-yr survival rate of individuals with CRC was 65% in the United States. The five-yr survival rate of stage I and II CRC ranges from 80%-90%, whereas stage III and IV metastatic diseases are associated with five-yr survival rates of 60%-71% and 8%-13%, respectively (9,10). Currently, in Taiwan, the overall five-yr survival rate of CRC is 63.0% (11). The five-yr survival rate was 74.3% for stage I CRC compared with 76.6% for stage II, 56.6% for stage III and only 16.7% for stage IV (12). The lifetime cost usually increases with advanced stages. The average cost of CRC in Spain, Iran, and Malaysia was 20.298€, $10715, and RM 13622 for stage I, 28.251€, $1592, and RM 19752 for stage II, 36.8948€, $1642, and RM 24972 for stage III, and 27.001€, $15723, and RM 27377 for stage IV, respectively (7, 13, 14). In Taiwan, the average cost of treating CRC in $/per year was $8416 for stage II, $14334 for stage III, and $21837 for stage IV, indicating large savings with early diagnosis and treatment (6).

CRC is considered primarily a “lifestyle” disease. Demographic variables, such as age, gender, familial CRC history, diets high in calories and animal fat, alcohol consumption, and obesity, in addition to other factors, such as tumor site, size, grade, histologic type, TNM stage, and carcinoembryonic antigen (CEA) level, have all been found to significantly affect survival in CRC (3,15-19). In the present study, we used population-based data from the Taiwan Cancer Data Base of the medical center hospital in North Taiwan to compare socio-demographic and clinicopathological characteristics, prognostic factors, and overall survival among 3 groups of CRC patients, i.e., those surviving 12, 36, and 60 months.

This study aimed to explore the survival rate and the potential factors influencing survival among CRC patients in northern Taiwan.

Materials and Methods

Study population

We conducted a single-center, retrospective cohort study to estimate the survival outcome of patients diagnosed with colorectal carcinoma at Cathay General Hospital in North Taiwan from 2007 to 2013. Data were extracted from medical records and the cancer database by trained data collectors. The eligibility criteria included the following: diagnosis and treatment of CRC; the International Classification of Disease for Oncology, 3rd Edition (ICD-O-3) topographical codes of C18.0-C20.9 (excluding C18.1) and morphology codes of 8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950 and 8980-8981. Participants who showed more than one type of cancer, ICD-O-3 morphology codes of 8935-8936, 8153, 8240-8242, 8013, 8246, 8249 and 9590-9720, a TₓNₓMₓ stage of 888 or 999, metastasis to the brain, or a survival time of fewer than six months were excluded. Demographic data extracted included gender, age at diagnosis, body mass index (BMI), smoking history, betel nut chewing status, drinking habits, and date of last contact or death. The evaluated tumor characteristics included primary site, histologic type, grade/differentiation, and size, as well as treatment type and regional lymph node or distant organ metastases. The disease staging was based on the American Joint Committee on Cancer (AJCC) criteria; cancer site-specific factors included CEA, circumferential resection margin (CRM), tumor regression grade, perineural nerve invasion, KRAS mutation, obstruction, and perforation. Survival data were obtained using death and date of last contact records to determine the current situation or date of death of each patient.
The study was reviewed and approved by the hospital’s institutional Review Board (No. CGH-P104060).

Statistical analyses were performed using SPSS software (ver. 22.0, Chicago, IL, USA). Quantitative values were compared using t-tests for independent groups. Categorical data were analyzed using the χ² test or Fisher’s exact test. Survival probabilities were estimated at intervals of 12, 36 and 60 months from the date of diagnosis to the date of death. Survival curves were constructed using the Kaplan-Meier method, and differences were analyzed by the log-rank test. Cox proportional hazards regression models were used to analyze survival by each variable. The level of statistical significance was set at P < 0.05. All reported P-values are two-tailed.

Results

Sample characteristics

A summary of the demographic and clinical characteristics of the participants is presented in Table 1.

The follow-up period continued to Dec 2015. We retrospectively evaluated 869 CRC patients from 2007 to 2013. Of these, 454 subjects were males (52.24%). Most patients ranged in age from 51 to 75 yr old (62.37%). The mean and median ages at diagnosis were 63.70 yr and 64 yr, respectively.

Table 1: Demographic and clinical characteristics of CRC patients (N = 869)

| Variable                        | Category                  | N (%) |
|---------------------------------|---------------------------|-------|
| Gender                          | Male                      | 454(52.4) |
| Age(yr)                         | Female                    | 415(47.76) |
| Median(range, y)                | 64(17-97)                 |       |
| Mean ± SD, y                    | 63.7±0.45                 |       |
| < 65 yr old                     | 435(50.06)                |       |
| ≥ 65 yr old                     | 434(49.94)                |       |
| Primary tumor site              | Colon                     | 554(63.75) |
| Tumor status                    | Rectum                    | 315(36.25) |
| T1/T2                           | 231(26.58)                |       |
| T3                              | 468(53.86)                |       |
| T4                              | 170(19.56)                |       |
| Regional lymph node metastasis | N0                        | 476(54.78) |
| N1                              | 208(23.94)                |       |
| N2                              | 185(21.29)                |       |
| Regional lymph node involvement| No                        | 476(54.78) |
| Yes                             | 393(45.22)                |       |
| Distant metastasis              | No                        | 747(85.96) |
| Yes                             | 122(14.04)                |       |
| Stage                           | I                         | 190(21.86) |
| II                              | 238(27.39)                |       |
| III                             | 303(34.87)                |       |
| IV                              | 138(15.88)                |       |
| Histology type                  | Adenocarcinoma            | 797(91.71) |
| Mucinous carcinoma              | 64(7.36)                  |       |
| Signet ring-cell carcinoma      | 8(0.92)                   |       |
Approximately 63.75% of the patients were diagnosed with cancer of the colon. One-third of patients were registered as living with stage III (34.87%) cancer, and the most common histopathological type reported was adenocarcinoma (91.71%).

**Survival outcome**

The mean survival time was 71.27±1.27 months. CRC-specific survival was 95.3%, 79.4% and 68.7% at 1, 3 and 5 yr (Fig. 1). The five-yr survival rate for patients with stage I, II, III and IV disease was 91.20%, 82.20%, 63.20% and 21.70%, respectively (Fig. 2).

### Table 1: (continued)

| Variable                          | Category  | N (%)   |
|----------------------------------|-----------|---------|
| No. of lymph nodes examined      | < 12      | 222(25.55) |
|                                  | ≥ 12      | 647(74.45) |
| Tumor size                       | < 50 mm   | 528(65.27) |
|                                  | ≥ 50 mm   | 281(34.73) |
| CEA                              | < 5.0 ng/ml | 34(3.91) |
|                                  | ≥ 5.0 ng/ml | 835(96.09) |
| CRM                              | Negative  | 826(94.55) |
|                                  | Positive  | 47(5.45)  |
| Perineural invasion              | No        | 496(54.68) |
|                                  | Yes       | 373(45.32) |
| KRAS mutation                    | No        | 43(4.95)  |
|                                  | Yes       | 25(2.88)  |
|                                  | Unknown   | 801(92.17) |
| Obstruction                      | No        | 512(58.92) |
|                                  | Yes       | 357(41.08) |
| Perforation                      | No        | 853(98.16) |
|                                  | Yes       | 16(1.84)  |
| BMI                              | 18.5-24   | 374(43.04) |
|                                  | ≥24       | 386(44.42) |
|                                  | Unknown   | 109(12.54) |
| Smoking                          | No        | 602(69.28) |
|                                  | Yes       | 160(18.41) |
|                                  | Unknown   | 107(12.31) |
| Drinking                         | No        | 642(73.88) |
|                                  | Yes       | 122(14.04) |
|                                  | Unknown   | 105(12.08) |
| Chewing betel nut               | No        | 733(84.35) |
|                                  | Yes       | 30(3.45)  |
|                                  | Unknown   | 106(12.20) |
Log-rank (Mantel-Cox) tests for the equality of the survival functions were conducted as well as a univariate Cox regression analysis. Combining the results of analysis of Log-rank tests and the univariate Cox regression, significant predictors of survival were the age at cancer diagnosis, tumor status, regional lymph node metastasis, distal organ metastasis, cancer stage, pathological differentiation, histopathologic type, tumor size, CRM, perineural nerve invasion, KRAS mutation, obstruction, and perforation (Table 2 and Table 3). The Cox forward stepwise regression model revealed a significant potentially curable disease and risk of CRC death (Table 4).
Table 2: Clinical and Pathological variables analysis (N = 869)

| Variable                        | Survival Rate | Overall Survival Rate / Std, Mo | P-value |
|---------------------------------|---------------|---------------------------------|---------|
|                                 | 12 Months     | 36 Months                       | 60 Months |               |
| Total                           |               |                                 |          |               |
| Gender                          |               |                                 |          |               |
| Male                            | 95.00         | 80.00                           | 69.90    | 70.28/1.86    | 0.981 |
| Female                          | 95.60         | 78.70                           | 67.60    | 69.65/1.71    |       |
| Age                             |               |                                 |          |               |
| < 65 yr old                     | 96.90         | 85.30                           | 76.50    | 76.74/1.64    | < 0.001 |
| ≥ 65 yr old                     | 93.70         | 73.50                           | 60.90    | 63.78/1.75    |       |
| Primary tumor site              |               |                                 |          |               |
| Colon                           | 95.50         | 80.50                           | 69.30    | 71.90/1.58    | 0.493 |
| Rectum                          | 94.80         | 77.60                           | 67.90    | 67.88/1.95    |       |
| Tumor status                    |               |                                 |          |               |
| T1/T2                           | 99.50         | 95.60                           | 88.80    | 83.71/1.49    | < 0.001 |
| T3                              | 96.30         | 80.00                           | 69.20    | 62.29/1.60    |       |
| T4                              | 86.80         | 55.80                           | 40.70    | 52.58/3.10    |       |
| Regional lymph node metastasis  |               |                                 |          |               |
| N0                              | 97.20         | 89.00                           | 82.50    | 77.83/1.34    | < 0.001 |
| N1                              | 97.60         | 79.20                           | 63.60    | 68.97/2.44    |       |
| N2                              | 87.90         | 55.70                           | 39.90    | 49.71/3.02    |       |
| Regional lymph node involvement |               |                                 |          |               |
| No                              | 97.20         | 89.00                           | 82.50    | 77.83/1.34    | < 0.001 |
| Yes                             | 93.00         | 68.10                           | 52.10    | 61.00/2.03    |       |
| Distant metastasis              |               |                                 |          |               |
| No                              | 97.40         | 85.20                           | 75.80    | 76.11/1.26    | < 0.001 |
| Yes                             | 82.20         | 41.30                           | 21.90    | 36.63/2.68    |       |
| Stage                           |               |                                 |          |               |
| I                               | 100.00        | 96.60                           | 91.20    | 84.82/1.54    | < 0.001 |
| II                              | 98.30         | 88.70                           | 82.20    | 76.59/1.79    |       |
| III                             | 95.60         | 78.10                           | 63.20    | 68.91/2.21    |       |
| IV                              | 82.80         | 40.10                           | 21.70    | 36.20/2.56    |       |
| Histology type                  |               |                                 |          |               |
| Adenocarcinoma                  | 95.60         | 80.90                           | 70.40    | 72.26/1.31    | 0.004 |
| Mucinous carcinoma              | 92.00         | 63.00                           | 53.00    | 58.42/4.53    |       |
| Signet ring-cell carcinoma      | 87.50         | 60.00                           | 30.00    | 42.41/8.59    |       |
| Pathological differentiation    |               |                                 |          |               |
| Low grade                       | 96.10         | 82.10                           | 71.20    | 72.94/1.31    | < 0.001 |
| High grade                      | 88.30         | 58.00                           | 49.10    | 54.99/3.79    |       |
Table 2: (continued)

| Variable                        | Survival Rate              | Overall Survival Rate / Std, Mo | P-value |
|---------------------------------|----------------------------|--------------------------------|---------|
|                                 | 12 Months | 36 Months | 60 Months |                                      |         |
| No. of lymph nodes examined     |            |           |           |                                      |         |
| < 12                            | 94.00      | 76.10     | 68.60     | 68.77/2.36                           | 0.708   |
| ≥ 12                            | 95.70      | 80.60     | 68.80     | 71.55/1.47                           |         |
| Tumor size                      |            |           |           |                                      |         |
| < 50 mm                         | 96.70      | 82.90     | 72.40     | 74.42/1.55                           | 0.003   |
| ≥ 50 mm                         | 93.90      | 75.10     | 63.70     | 64.81/2.15                           |         |
| CEA                              |            |           |           |                                      |         |
| < 5.0 ng/ml                     | 100.00     | 90.00     | 78.80     | 73.87/7.01                           | 0.436   |
| ≥ 5.0 ng/ml                     | 96.30      | 80.10     | 68.70     | 69.56/1.32                           |         |
| CRM                              |            |           |           |                                      |         |
| Negative                         | 95.60      | 80.70     | 70.20     | 72.41/1.31                           | < 0.001 |
| Positive                         | 89.40      | 57.40     | 45.30     | 52.78/4.98                           |         |
| Perineural invasion              |            |           |           |                                      |         |
| No                              | 98.60      | 92.70     | 86.60     | 80.97/1.23                           | < 0.001 |
| Yes                             | 93.50      | 66.70     | 50.10     | 58.57/2.09                           |         |
| KRAS mutation                    |            |           |           |                                      |         |
| No                              | 90.20      | 26.70     | 0.00      | 25.60/1.79                           | 0.005   |
| Yes                             | 90.00      | 76.40     | 40.70     | 47.86/5.31                           |         |
| Obstruction                      |            |           |           |                                      |         |
| No                              | 96.20      | 84.50     | 75.30     | 73.85/1.42                           | < 0.001 |
| Yes                             | 94.30      | 71.30     | 58.30     | 64.08/2.17                           |         |
| Perforation                      |            |           |           |                                      |         |
| No                              | 95.30      | 79.60     | 69.50     | 71.62/1.27                           | 0.028   |
| Yes                             | 93.30      | 68.90     | 17.20     | 44.61/6.10                           |         |
| BMI                              |            |           |           |                                      |         |
| 18.5-24                         | 96.10      | 82.70     | 72.90     | 71.70/1.56                           | 0.227   |
| ≥24                             | 98.30      | 86.60     | 75.80     | 76.91/1.96                           |         |
| Smoking                          |            |           |           |                                      |         |
| No                              | 96.90      | 83.80     | 73.90     | 73.94/1.31                           | 0.646   |
| Yes                             | 97.40      | 86.30     | 76.80     | 71.07/3.16                           |         |
| Drinking                         |            |           |           |                                      |         |
| No                              | 96.80      | 84.20     | 73.50     | 73.74/1.28                           | 0.785   |
| Yes                             | 98.30      | 85.50     | 79.50     | 69.90/3.83                           |         |
| Chewing betel nut               |            |           |           |                                      |         |
| No                              | 96.90      | 83.90     | 73.70     | 75.09/1.31                           | 0.229   |
| Yes                             | 100.00     | 96.00     | 86.40     | 67.91/2.86                           |         |
The following factors were associated with a relative excess hazard for death: age $\geq$ 65 yr (HR = 2.36, 95% CI: 1.76-3.17, $P<0.001$); high grade of pathological differentiation (HR=1.84, 95% CI: 1.27-2.66, $P=0.001$); perineural nerve invasion (HR=2.90, 95% CI: 2.03-4.14, $P<0.001$); metastasis to distant organs (HR=2.78, 95% CI: 2.00-3.87, $P<0.001$); intestinal obstruction (HR=1.38, 95% CI: 1.04-1.84, $P=0.026$); and multiple regional lymph node metastases (HR=1.81, 95% CI: 0.28-2.57, $P=0.001$).

Table 3: Cox regression univariate analysis

| Variable                                    | Wald   | HR    | 95% CI          | P-value |
|----------------------------------------------|--------|-------|------------------|---------|
| Age                                          |        |       |                  |         |
| < 65 yr old                                  | 19.85  | 1.87  | 1.42-2.47        | < 0.001 |
| $\geq$ 65 yr old                            |        |       |                  |         |
| Tumor status                                 |        |       |                  |         |
| T1/T2                                        |        |       |                  |         |
| T3                                           | 25.03  | 3.54  | 2.16-5.82        | < 0.001 |
| T4                                           | 68.61  | 8.74  | 5.23-14.60       | < 0.001 |
| Regional lymph node metastasis               |        |       |                  |         |
| No                                           |        |       |                  |         |
| Yes                                          | 58.54  | 3.05  | 2.29-4.05        | < 0.001 |
| Distant metastasis                           |        |       |                  |         |
| No                                           |        |       |                  |         |
| Yes                                          | 133.49 | 5.57  | 4.16-7.45        | < 0.001 |
| Stage                                        |        |       |                  |         |
| I                                            |        |       |                  |         |
| II                                           | 8.14   | 2.55  | 1.34-4.86        | 0.004   |
| III                                          | 27.19  | 5.01  | 2.73-9.18        | < 0.001 |
| IV                                           | 88.83  | 18.96 | 10.28-34.96      | < 0.001 |
| Histology type                               |        |       |                  |         |
| Adenocarcinoma                               |        |       |                  |         |
| Mucinous carcinoma                           | 6.96   | 1.77  | 1.16-2.71        | 0.008   |
| Signet ring-cell carcinoma                   | 4.15   | 2.80  | 1.04-7.55        | 0.042   |
| Pathological differentiation                 |        |       |                  |         |
| Low grade                                    |        |       |                  |         |
| High grade                                   | 20.25  | 2.20  | 1.56-3.10        | < 0.001 |
| Tumor size                                   |        |       |                  |         |
| < 50 mm                                      |        |       |                  |         |
| $\geq$ 50 mm                                 | 8.75   | 1.53  | 1.15-2.03        | 0.003   |
| CRM                                          |        |       |                  |         |
| Negative                                     |        |       |                  |         |
| Positive                                     | 13.29  | 2.18  | 1.43-3.31        | < 0.001 |
| Perineural invasion                          |        |       |                  |         |
| No                                           |        |       |                  |         |
| Yes                                          | 83.05  | 4.43  | 3.22-6.10        | < 0.001 |
| KRAS mutation                                |        |       |                  |         |
| No                                           |        |       |                  |         |
| Yes                                          | 7.22   | 3.90  | 1.45-10.51       | 0.007   |
| Obstruction                                  |        |       |                  |         |
| No                                           |        |       |                  |         |
| Yes                                          | 21     | 1.87  | 1.43-2.44        | < 0.001 |
| Perforation                                  |        |       |                  |         |
| No                                           |        |       |                  |         |
| Yes                                          | 4.58   | 2.28  | 1.07-4.84        | 0.032   |

Table 4: Forward stepwise Cox regression analysis

| Variable                                    | HR     | 95% CI        | Wald  | P-value |
|----------------------------------------------|--------|---------------|-------|---------|
| Age                                          |        |               |       |         |
| < 65 yr old                                  | 2.36   | 1.76-3.17     | 32.68 | < 0.001 |
| $\geq$ 65 yr old                            |        |               |       |         |
| Pathological differentiation                 |        |               |       |         |
| Low grade                                    |        |               |       |         |
| High grade                                   | 1.84   | 1.27-2.66     | 10.54 | 0.001   |
| Perineural invasion                          |        |               |       |         |
| No                                           | 2.90   | 2.03-4.14     | 34.26 | < 0.001 |
| Yes                                          |        |               |       |         |
| Distant metastasis                           |        |               |       |         |
| No                                           | 2.78   | 2.00-3.87     | 36.48 | < 0.001 |
| Yes                                          |        |               |       |         |
| Obstruction                                  |        |               |       |         |
| No                                           | 1.38   | 1.04-1.84     | 4.94  | 0.026   |
| Yes                                          |        |               |       |         |
| Regional lymph node metastasis               |        |               |       |         |
| No                                           | 1.81   | 1.28-2.57     | 11.22 | 0.001   |
| Yes                                          |        |               |       |         |
Discussion

This study observed factors connected with disease survival in a population-wide cohort with access to universal healthcare with a specific focus on recognizing the five-yr survival rate and risk factors of CRC. In a Taiwanese population-based sample of patients with stage I-IV CRC, overall cancer survival reached 71.27±1.27 months. Certain characteristics related to disease progression were strongly associated with the 5-yr risk of death from CRC: age ≥ 65 yr, high grade of pathological differentiation, perineural nerve invasion, distant metastasis, obstruction and multiple regional lymph node metastases each independently increased the risk of death by factors of 1.38 to almost 3. No correlations were found in this study between characteristic variables (e.g., BMI or smoking, drinking, betel nut chewing habits) and CRC survival.

CRC was more common in men than women in our study, which was in agreement with the age-specific incidence rates reported by the Taiwan Health Promotion Administration in 2013. The median age in our study was 64 yr old; however, this age is slightly lower than that observed from cases during 2013, where the mean age of CRC patients was 66 yr (8). The five-yr survival rate found in this study was higher than (12) who reported a survival rate of 55.70% among patients with CRC. This result is probably due to differences in the study populations, as the majority of patients in their study were ≥65 yr old. By age group, the five-yr survival rate was 76.50% in patients younger than 65 and 60.90% in patients ≥ 65 yr old (P<0.001). After adjustment with the relevant control variables, we found that being ≥ 65 yr old was associated with a relative excess hazard for death of 2.36 (95% CI: 1.76-3.17, P<0.001). Similarly, patient age at diagnosis appears to be an important prognostic factor for all patients (12, 19, 20). In our study, we found that nearly 17% of the patients were younger than 50 yr old, with a minimum age of 17 yr. It is important to note the occurrence of CRC at a young age in our population. Patients younger than 50 yr would not yet qualify for screening and would be more likely to present with symptomatic disease and have a poorer prognosis (21). Therefore, reducing the age at which patients should be screened for this condition could lead to improved outcomes. Such strategies as fecal occult blood testing using immunochemical methods could easily be implemented.

The overall five-yr survival rate in our study was 68.70%; this result is better than that reported by the HPA (8), in Taiwan (12), and the American Cancer Society, which estimated survival rates of 63.0%, 55.69%, and 66%, respectively. In our study, the overall stage-specific five-yr survival rate was 91.20% for stage I, 82.20% for stage II, 63.20% for stage III, and 21.70% for stage IV. Stage I and stage II CRC had an 80%-90% five-yr survival rate, whereas stage III and stage IV metastatic diseases were associated with five-yr survival rates of 60% and 8%, respectively (10). In comparison, the survival rates found in the present study were higher than those previously reported. The risk of death in stage I, II, III, and IV CRC was 2.55 (95% CI: 1.34-4.86, P<0.001), 5.01 (95% CI: 2.73-9.18, P<0.001), and 18.96 (95% CI: 10.28-34.96, P<0.001), respectively. Similarly, the number of lymph node metastases in CRC was an important factor of CRC survival (22, 23). In addition to AJCC stage, other factors influence the survival rate. Thus, the survival rate was investigated pathology results, such as tumor site, size, grade, histology, lymph node metastasis, perineural nerve invasion and other variables in addition to the AJCC stage, T stage, N stage, and M stage as independent variables (20, 22, 24, 25).

In most cases, early-stage CRC does not present obvious symptoms; as such, muscle infiltration or distant metastases have occurred by the time of diagnosis. In this study, tumor status, regional lymph node metastasis, and distant metastasis independently affect the survival rate of CRC patients. These results are consistent with CRC survival rate estimates reported (26-28). The present findings show that high-grade pathological differentiation was associated with a relative excess hazard for death of 1.84 (95% CI: 1.27-2.66, P=0.001). Similarly, grade level could independently affect the survival rate of CRC patients.
(26, 28, 29). Early CRC staging has a positive effect on survival rate. Therefore, the earlier detection of CRC should lead to substantial improvements in survival. CRC screenings were at < 50 yr of age (12, 19, 24).

In the present study, the univariate analysis revealed that histology type was a significant factor. There were significant percentages of mucinous adenocarcinoma (7.36%) and signet ring cell carcinoma (0.92%). These findings are similar to those of previous CRC studies (12, 24, 28). The risk of death in mucinous adenocarcinoma and signet ring-cell CRC with adenocarcinoma was 1.77 (95% CI: 1.16-2.71, P=0.008) and 2.80 (95% CI: 1.04-7.55, P=0.042), respectively. The histology type of CRC was a risk factor for survival rate (12, 28). However, in the forward stepwise Cox regression analysis, histology type did not independently affect the survival rate of CRC patients.

In this study, perineural nerve invasion was associated with a relative excess hazard for death of 4.43 (95% CI: 3.22-6.10, P<0.001). Furthermore, our forward stepwise Cox regression analysis showed that perineural nerve invasion was associated with improved predictions of CRC prognosis, which was in agreement with previous reports (12, 30-32). After adjustment with the relevant control variables, peripheral nerve invasion remained an independent predictor of patient survival and prognosis. The importance of this factor should be considered by clinicians when assessing the prognosis of patients.

Obstruction was a significant factor affecting the survival of CRC patients. In the present study, the univariate Cox regression analysis demonstrated better survival in patients without obstruction (HR = 1.87, 95% CI: 1.43-2.44, P<0.001). After adjustment with the relevant control variables, obstruction was associated with a relative excess hazard for death of 1.38 (95% CI: 1.04-1.84, P=0.026). These findings are similar to other studies (33, 34).

One limitation of this study was the small sample size; in addition, the findings were generated using data from a single medical center hospital in North Taiwan. Thus, the results of some survival comparisons were not significant. These limitations should be considered when applying these results to other districts in Taiwan that may have demographic differences. Furthermore, multicenter studies should be conducted to merge patient datasets for further research in Taiwan.

**Conclusion**

There are numerous prognostic parameters affecting survival in colorectal cancers. Presence of perineural nerve invasion, distant metastasis, age, pathological differentiation grade, obstruction and regional lymph node metastasis are independent predictors of the survival and prognosis of patients with CRC. Perineural nerve invasion and distant metastasis appeared to be important prognostic factors affecting the entire patient cohort. Therefore, the earlier detection of CRC should lead to substantial improvements in survival.

**Ethical considerations**

Ethical issues (including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

**Acknowledgments**

This study received no financial support.

**Conflict of Interests**

The authors declare that there are no conflicts of interests.

**References**

1. International Agency for Research on Cancer (2013). GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. World Health Organization. http://globocan.iarc.fr/Default.aspx
2. Siegel RL, Miller KD, Jemal A (2016). Cancer statistics 2016. CA Cancer J Clin, 66(1):7-30.
3. Stewart BW, Wild CP (2014). World cancer report 2014. International Agency for Research on Cancer, World Health Organization. http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014
4. Torre LA, Bray F, Siegel RL et al (2015). Gobal cancer statistics, 2012. CA Cancer J Clin, 65: 87-108.
5. Bishehsari F, Mahdavinia M, Vacca M et al (2014) Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol, 20(20): 6055-6072.
6. Pourhoseingholi MA (2012). Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol, 4(4): 68-70.
7. Veertil SK, Lim KG, Chaiyakunapruk N et al (2017). Colorectal cancer in Malaysia: Its burden and implications for a multiethnic country. Asian J Surg, 40(6):481-489.
8. Health Promotion Administration, Ministry of Health and Welfare (2016). Cancer registry annual report, 2013. https://www.hpa.gov.tw/Pages/ashx/File.axd?FilePath=~/File/Attach/7425/File_6951.pdf
9. Cancer. Net. (2015). Colorectal cancer – statistics. https://www.cancer.net/cancer-types/colorectal-cancer/statistics
10. Mathur A, Ware C, Davis L et al (2014). FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. PLoS One, 9(6): e98515.
11. Taiwan Cancer Registry. (2015). Cancer survival rates in Taiwan. http://tcrr.cph.ntu.edu.tw/uploadimages/Survival_98_102.pdf
12. Fang SC, Chao TB, Tung HY et al (2014). Analysis of prognostic factors to predict postoperative colorectal cancer patients survival. Med J South Taiwan, 10(2): 75-86.
13. Davari M, Maracy MR, Emami MH et al (2012). The Direct Medical Costs of Colorectal Cancer in Iran; Analyzing the Patient’s Level Data from a Cancer Specific Hospital in Isfahan. Int J Prev Med, 3(12):887-892.
14. Corral J, Borràs JM, Chiarello P et al (2015). Estimacion del coste hospitalario del cancer colorectal en Cataluña (Spain). Gac Sanit, 29(6):437-444.
15. Chen PC, Lee JC, Wang JD (2015). Estimation of Life-Year Loss and Lifetime Costs for Different Stages of Colon Adenocarcinoma in Taiwan. PloS One, 10(7): e0133755.
16. Beckmann KR, Bennett A, Young GP et al (2016). Sociodemographic disparities in survival from colorectal cancer in South Australia: A population-wide data linkage study. BMC Health Serv Res, 16:24.
17. International Agency for Research on Cancer. (2015). IARC monographs evaluate consumption of red meat and processed meat. World Health Organization. http://www.iarc.fr/en/media-centre/pr/2015/pdfs/pr240_E.pdf
18. Perron I, Daigle JM, Vandal N et al (2015). Characteristics affecting survival after locally advanced colorectal cancer in Quebec. Curr Oncol, 22(6): e485-e492.
19. Wang R, Wang MJ, Ping J (2015). Clinicopathological features and survival outcomes of colorectal cancer in Young versus elderly: A population-based cohort study of SEER 9 registries data (1988-2011). Medicine (Baltimore), 94(35): e1402.
20. Korrprat P, Pollheimer MJ, Lindtner RA et al (2011). Value of tumor size as a prognostic variable in colorectal cancer: A critical reappraisal. Ann J Clin Onol, 34(1): 43-9.
21. Plummer JM, Leake PA, Ferron-Boothe D et al (2016). Colorectal cancer survival in Jamaica. Ann Med Surg (Lond), 6: 26-9.
22. Kao LC, Yang PF, Ma CJ et al (2013). The impact of metastatic ratio to retrieved regional lymph nodes on overall survival in patients with stage III. Journal Society of Colon and Rectal Surgeons, R.O.C, 24(2): 37-43.
23. Tsai TC, Lin WL, Chang SC et al (2014). The survival of stage II colorectal cancer patients is significantly affected by the numbers of lymph node retrieval. Medical Journal of South Taiwan, 10(2): 67-74.
24. Chou CI, Weng SF, Cheng LC et al (2013). National data on colorectal cancer trends: A population-based study in Taiwan. Journal of Society of Colon and Rectal Surgeons, R.O.C, 24(1): 1-8.
25. Hsu YJ, Tsai WS, Hsieh PS et al (2016). Worse survival in rectal cancer patients with pre-operative radiotherapy compared to without radiotherapy in same postoperative pathological pN1 classification. *Journal of Society of Colon and Rectal Surgeons*, R.O.C, 27(1): 7-14.

26. Zare-Bandamiri M, Khanjani N, Jahani Y et al (2016). Factors affecting survival in patients with colorectal cancer in Shiraz, Iran. *Asian Pac J Cancer Prev*, 17(1): 159-63.

27. Agüero F, Murta-Nascimento C, Gallén M et al (2012). Colorectal cancer survival: Results from a hospital-based cancer registry. *Rev Esp Enferm Dig*, 104(11): 572-7.

28. Yuan Y, Li MD, Hu HG et al (2013). Prognostic and survival analysis of 837 Chinese colorectal cancer patients. *World J Gastroenterol*, 19(17): 2650-9.

29. Kinoshita O, Kishimoto M, Murayama Y et al (2015). Poorly differentiated clusters with larger extents have a greater impact on survival: A semi-quantitative pathological evaluation for 239 patients with non-mucinous pT2-3 colorectal carcinoma. *World J Surg Oncol*, 13: 140.

30. Hiranyakas A, da Silva G, Wexner SD et al (2013). Factors influencing circumferential resection margin in rectal cancer. *Colorectal Dis*, 15(3): 298-303.

31. Huh JW, Kim YJ, Kim HR (2010). Ratio of metastatic to resected lymph nodes as a prognostic factor in node-positive colorectal cancer. *Ann Surg Oncol*, 17(10): 2640-6.

32. Liebig C, Ayala G, Wilks J et al (2009). Perineural invasion is an independent predictor of outcome in colorectal cancer. *J Clin Oncol*, 27(31): 5131-7.

33. Cennamo V, Luigiano C, Coccolini F et al (2013). Meta-analysis of randomized trials comparing endoscopic stenting and surgical decompression for colorectal cancer obstruction. *Int J Colorectal Dis*, 28(6): 855-63.

34. Fu CY, Jao SW, Wu CC et al (2011). Comparisons of characteristics and outcome of colorectal cancer in different age categories: A retrospective analysis of a single institution in Taiwan. *Journal of Society of Colon and Rectal Surgeons*, R.O.C, 22(3): 57-64.